ArticleAmerican journal of neurodegenerative disease2022
Effect of Modafinil on functional connectivity in healthy young people using resting-state fMRI data.
Article in American journal of neurodegenerative disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExamining the differences in the Functional Connectivity (FC) network while using Functional Magnetic Resonance Imaging (fMRI) between two groups can expand the understanding of neural processes and help diagnose and prevent neurological progression disorders. The present study evaluated the Modafinil effect on the FC of brain Regions of Interest (ROI) among healthy young individuals between the Modafinil and placebo groups.
methodThe data used in this study were downloaded from the open fMRI site and analyzed after preprocessing. Data included brain scan images of 26 healthy young men with no history of neurological disorders. These people are divided into two groups of drugs and a placebo. The drug group was given 100 mg of Modafinil, and the placebo group was assigned the same dose. Data were analyzed using a longitudinal variance component model.
resultAfter taking the drug and placebo by the two groups, the study of the difference between FC in the drug and placebo group and the baseline effect showed a statistically significant difference in one pair of ROIs. Also, in examining the difference between FC in the drug and placebo groups of the longitudinal trend, there was a statistically significant difference between 5 pairs of ROIs.
conclusionAfter taking Modafinil and placebo, it was observed that FC in most areas in the drug group increased compared to the placebo group, indicating Modafinil has cognitive enhancement properties and has a role in visual, auditory, memory learning, and self-awareness functions and enhances these functions.
Indexed as
Identifiers
35600512PMC9123432W4286837316What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.